$5750 | Single User
$11500 | Site License
$17250 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025
[Report Updated: 31-07-2017]

Published by Delve Insight: 31 Jul 2017 | 116210 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

DelveInsight’s “Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Metastatic Renal Cell Carcinoma (mRCC) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Metastatic Renal Cell Carcinoma (mRCC) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Metastatic Renal Cell Carcinoma (mRCC) for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Metastatic Renal Cell Carcinoma (mRCC) market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Metastatic Renal Cell Carcinoma (mRCC) , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Metastatic Renal Cell Carcinoma (mRCC) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Metastatic Renal Cell Carcinoma (mRCC) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Metastatic Renal Cell Carcinoma (mRCC) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

• Understanding historical and forecasted epidemiological data for Metastatic Renal Cell Carcinoma (mRCC) covering 7MM from 2015-2025.

• Segment level epidemiology and market split for Metastatic Renal Cell Carcinoma (mRCC) .

• The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Metastatic Renal Cell Carcinoma (mRCC) .

• The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Metastatic Renal Cell Carcinoma (mRCC) market trends.

• Thorough market distribution based on market share for Metastatic Renal Cell Carcinoma (mRCC) .

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Renal Cell Carcinoma (mRCC) market.

• To understand the future market competition in the Metastatic Renal Cell Carcinoma (mRCC) market and Insightful review of the key market drivers and barriers.

• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Renal Cell Carcinoma (mRCC) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 31-07-2017]

  • 1. Report Introduction

    2. Metastatic Renal Cell Carcinoma (mRCC) Market Overview at a Glance

    2.1. Total Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) for 7 MM in 2016

    2.2. Total Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) for 7 MM in 2025

    3. Metastatic Renal Cell Carcinoma (mRCC)

    3.1.1. Overview

    3.1.2. Symptoms

    3.1.3. Pathophysiology

    3.1.4. Staging

    3.1.5. Diagnosis

    3.1.6. Treatment

    4. Epidemiology and Patient Population

    4.1.1. United States

    4.1.1.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in United States

    4.1.2. Germany

    4.1.2.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in Germany

    4.1.3. France

    4.1.3.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in France

    4.1.4. Italy

    4.1.4.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in Italy

    4.1.5. Spain

    4.1.5.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in Spain

    4.1.6. United Kingdom

    4.1.6.1. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom

    5. Treatment Algorithm

    5.1.1. Treatment Guidelines/Practices

    6. Marketed Drugs for Metastatic Renal Cell Carcinoma (mRCC)

    6.1. Drug 1: Company A

    6.1.1. Drug Description

    6.1.2. Mechanism of Action

    6.1.3. Regulatory Milestones

    6.1.4. Advantages & Disadvantages

    6.1.5. Safety and Efficacy

    6.1.6. Product Profile

    6.1.7. Patent Status

    6.2. Drug 2: Company B

    6.2.1. Drug Description

    6.2.2. Mechanism of Action

    6.2.3. Regulatory Milestones

    6.2.4. Advantages & Disadvantages

    6.2.5. Safety and Efficacy

    6.2.6. Product Profile

    6.2.7. Patent Status

    7. Emerging Therapies

    7.1. Drug 3: Company C

    7.1.1. Description

    7.1.2. Regulatory Milestones

    7.1.3. Advantages & Disadvantages

    7.1.4. Product Profile

    7.1.5. Launch Date

    7.1.6. Clinical Development

    7.1.7. Clinical Pipeline Activity

    7.1.8. Ongoing Trials Information

    7.1.9. Clinical Trial by Phase

    7.2. Drug 4: Company B

    7.2.1. Description

    7.2.2. Regulatory Milestones

    7.2.3. Advantages & Disadvantages

    7.2.4. Product Profile

    7.2.5. Launch Date

    7.2.6. Clinical Development

    7.2.7. Clinical Pipeline Activity

    7.2.8. Ongoing Trials Information

    7.2.9. Clinical Trial by Phase

    8. Overview of Total Metastatic Renal Cell Carcinoma (mRCC) Market (2016 & 2025)

    9. Metastatic Renal Cell Carcinoma (mRCC) : Country-Wise Market Analysis

    9.1. United States

    9.1.1. Historical Market Size (2015-2016)

    9.1.2. Forecasted Market Size (2017-2025)

    9.2. Germany Market Size

    9.2.1. Historical Market Size (2015-2016)

    9.2.2. Forecasted Market Size (2017-2025)

    9.3. France Market Size

    9.3.1. Historical Market Size (2015-2016)

    9.3.2. Forecasted Market Size (2017-2025)

    9.4. United Kingdom Market Size

    9.4.1. Historical Market Size (2015-2016)

    9.4.2. Forecasted Market Size (2017-2025)

    9.5. Spain Market Size

    9.5.1. Historical Market Size (2015-2016)

    9.5.2. Forecasted Market Size (2017-2025)

    9.6. Italy Market Size

    9.6.1. Historical Market Size (2015-2016)

    9.6.2. Forecasted Market Size (2017-2025)

    9.7. Japan Market Size

    9.7.1. Historical Market Size (2015-2016)

    9.7.2. Forecasted Market Size (2017-2025)

    10. Market Drivers

    11. Market Restraints

    12. Appendix

    13. Report Methodology

    14. Consulting Services

    15. Disclaimer

    16. About DelveInsight

List Of Tables
in Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 31-07-2017]

Table 1: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in United States (2015-2025)

Table 2: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Germany (2015-2025)

Table 3: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in France (2015-2025)

Table 4: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom (2015-2025)

Table 5: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Spain (2015-2025)

Table 6: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Italy (2015-2025)

Table 7: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Japan (2015-2025)

Table 8: List of Marketed Drugs for Metastatic Renal Cell Carcinoma (mRCC)

Table 9: List of Pipeline Phase III Drugs for Metastatic Renal Cell Carcinoma (mRCC)

Table 10: Drug 1, Clinical Trials by Zone, 2017

Table 11: Clinical Trials by Trial status, 2017

Table 12: Drug 2, Clinical Trials by Zone, 2017

Table 13: Clinical Trials by Trial status, 2017

Table 14: Drug 3, Clinical Trials by Zone, 2017

Table 15: Clinical Trials by Trial status, 2017

Table 16: United States Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 17: Germany Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 18: France Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 19: United Kingdom Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 20: Spain Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 21: Italy Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Table 22: Japan Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

List Of Figures, Charts and Diagrams
in Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 31-07-2017]

Figure 1: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in United States (2015-2025)

Figure 2: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Germany (2015-2025)

Figure 3: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in France (2015-2025)

Figure 4: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom (2015-2025)

Figure 5: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Spain (2015-2025)

Figure 6: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Italy (2015-2025)

Figure 7: Diagnosed Cases Metastatic Renal Cell Carcinoma (mRCC) in Japan (2015-2025)

Figure 8: List of Marketed Drugs for Metastatic Renal Cell Carcinoma (mRCC)

Figure 9: List of Pipeline Phase III Drugs for Metastatic Renal Cell Carcinoma (mRCC)

Figure 10: Drug 1, Clinical Trials by Zone (%), 2017

Figure 11: Clinical Trials by Trial status, 2017

Figure 12: Drug 2, Clinical Trials by Zone (%), 2017

Figure 13: Clinical Trials by Trial status, 2017

Figure 14: Drug 3, Clinical Trials by Zone (%), 2017

Figure 15: Clinical Trials by Trial status, 2017

Figure 16: United States Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 17: Germany Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 18: France Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 19: United Kingdom Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 20: Spain Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 21: Italy Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Figure 22: Japan Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD, Million (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

116210 | DIMI0138

Number of Pages

70

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 31-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)